A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1560 participants.
Also called NCT07743450
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,560 participants
- Sponsor
- Ascletis Pharma (China) Co., Limited
- Registry
-
NCT07743450
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Czechia, Germany, Greece, Poland, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07743450. Randomized; triple masking; primary purpose treatment. Start 2026-08-28 (actual); primary completion 2028-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Acronym
- AURORA-2
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Chronic Weight Management
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- ASC30 tablets A1
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
Record details
- Record id
cardio:ct-nct07743450- Content hash
0a656e6b7f637799581c997833262d080f44793eb1f857a14aeadfc65aafbe5f